In this context, new biomarkers associated with the anticancer effects of 2ME, such as F-spondin, which respond to 2ME in primary cell cultures from endometrium cancer patients, could be used as a therapeutic strategy to enhance the probabilities of clinical management in patients in early stages of endometrial cancer. The gene discussed is SPON1; the disease is endometrial cancer.